Merck Appears Ready To Return To June Highs (Technical Analysis)
Merck's 15% decline in July is presenting investors with an intermediate to long-term buying opportunity. Long-term trend lines and Bollinger Bands indicate strong support at $110. We expect Merck ...
Merck (MRK) Increases Yet Falls Behind Market: What Investors Need to Know
In the most recent trading session, Merck (MRK) closed at $115.86, indicating a +0.53% shift from the previous trading day.
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped Merck...
Merck Stock Falls After Rival Beats Keytruda Cancer Drug in Trial
Summit Therapeutics said its Ivonescimab treatment reduced the risk of disease progression or death by 49% compared with the market leader.
Merck & Co., Inc. (MRK) CEO Rob Davis presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 2:35 PM ET Company Participants Rob Davis - Chairman and CEO Dean Li - President of Merck Res...
What's Wrong With Merck's Stock?
Merck's business is growing, but the stock's gains have been modest this year. The drug manufacturer remains heavily reliant on Keytruda, which accounts for nearly half of its revenue.
Merck (MRK) Advances But Underperforms Market: Key Facts
In the most recent trading session, Merck (MRK) closed at $118.45, indicating a +0.84% shift from the previous trading day.
MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate
Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a rare blood disorder.
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombo...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for Certain Patients With Essential Thrombocythemia.
Buying Wonderful Businesses At Fair Prices - The Billionaire Way
Warren Buffett's success stems from evolving his strategy to focus on buying high-quality businesses at fair prices rather than just seeking deep-value investments. By deeply understanding business...
Merck says it's discontinuing a late-stage trial of a lung cancer treatment after high number of adverse events
Merck & Co. MRK, +1.21% said Thursday it's discontinuing a late-stage trial of a treatment for patients with extensive-stage small cell lung cancer after patients experienced a high rate of adverse...
Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patien...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Update on Phase 3 KeyVibe-008 Trial Evaluating Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With ES-SCLC.
Merck's Blockbuster Vaccine Gardasil Sales In China: Analyst Highlights Challenges and Opportunities
Goldman Sachs recently discussed with Joe Romanelli, President of Human Health International at Merck & Co Inc MRK, to review Gardasil's performance and future outlook in China.
Related Companies